{"id":960671,"date":"2026-05-11T08:06:00","date_gmt":"2026-05-11T12:06:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-reports-first-quarter-2026-results\/"},"modified":"2026-05-11T08:06:00","modified_gmt":"2026-05-11T12:06:00","slug":"exagen-inc-reports-first-quarter-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-reports-first-quarter-2026-results\/","title":{"rendered":"Exagen Inc. Reports First Quarter 2026 Results"},"content":{"rendered":"

\nDelivers record total revenue and AVISE(R) CTD average selling price
\n<\/h2>\n
\n

CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\n Three Months Ended March 31,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>
\n \n <\/td>\n<\/tr>\n
\n Unaudited. In thousands, except ASP data.<\/em>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Revenue<\/td>\n\u00a0<\/td>\n$<\/td>\n17,306<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n15,498<\/td>\n\u00a0<\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n59.0<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n58.9<\/td>\n%<\/td>\n<\/tr>\n
Operating expenses<\/td>\n\u00a0<\/td>\n$<\/td>\n13,619<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n12,488<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating loss<\/td>\n\u00a0<\/td>\n$<\/td>\n(3,414<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(3,365<\/td>\n)<\/td>\n<\/tr>\n
Net loss<\/td>\n\u00a0<\/td>\n$<\/td>\n(3,967<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(3,752<\/td>\n)<\/td>\n<\/tr>\n
Adjusted EBITDA<\/td>\n\u00a0<\/td>\n$<\/td>\n(2,160<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(2,508<\/td>\n)<\/td>\n<\/tr>\n
Trailing-twelve-month average selling price (ASP)<\/td>\n\u00a0<\/td>\n$<\/td>\n444<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n419<\/td>\n\u00a0<\/td>\n<\/tr>\n
Cash and cash equivalents<\/td>\n\u00a0<\/td>\n$<\/td>\n21,513<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n11,194<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n First Quarter 2026 Highlights:<\/strong>\n <\/p>\n